Novel Insights into Heterozygous Factor XIII Deficiency

The prevalence and clinical significance of heterozygous factor XIII (FXIII) deficiency has long been debated, with controversial reports emerging since 1988. In the absence of large epidemiologic studies, but based on a few studies, a prevalence of 1 per 1,000 to 5,000 is estimated. In southeastern Iran, a hotspot area for the disorder, a study of more than 3,500 individuals found an incidence of 3.5%. Between 1988 and 2023, a total of 308 individuals were found with heterozygous FXIII deficiency, of which molecular, laboratory, and clinical presentations were available for 207 individuals. A total of 49 variants were found in the F13A gene, most of which were missense (61.2%), followed by nonsense (12.2%) and small deletions (12.2%), most occurring in the catalytic domain (52.1%) of the FXIII-A protein and most frequently in exon 4 (17%) of the F13A gene. This pattern is relatively similar to homozygous (severe) FXIII deficiency. In general, heterozygous FXIII deficiency is an asymptomatic condition without spontaneous bleeding tendency, but it can lead to hemorrhagic complications in hemostatic challenges such as trauma, surgery, childbirth, and pregnancy. Postoperative bleeding, postpartum hemorrhage, and miscarriage are the most common clinical manifestations, while impaired wound healing has been rarely reported. Although some of these clinical manifestations can also be observed in the general population, they are more common in heterozygous FXIII deficiency. While studies of heterozygous FXIII deficiency conducted over the past 35 years have shed light on some of the ambiguities of this condition, further studies on a large number of heterozygotes are needed to answer the major questions related to heterozygous FXIII deficiency.

Keywords

factor XIII deficiency - heterozygous factor XIII deficiency - miscarriage - postpartum hemorrhage

Publikationsverlauf

Artikel online veröffentlicht:
20. März 2023

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

References
1 Dorgalaleh A, Rashidpanah J. Blood coagulation factor XIII and factor XIII deficiency. Blood Rev 2016; 30 (06) 461-475

Google Scholar
2 Dorgalaleh A, Naderi M, Hosseini MS. et al. Factor XIII deficiency in Iran: a comprehensive review of the literature. Semin Thromb Hemost 2015; 41 (03) 323-329

Google Scholar
3 Shetty S, Shelar T, Mirgal D. et al. Rare coagulation factor deficiencies: a countrywide screening data from India. Haemophilia 2014; 20 (04) 575-581

Google Scholar
4 Viswabandya A, Baidya S, Nair SC. et al. Correlating clinical manifestations with factor levels in rare bleeding disorders: a report from Southern India. Haemophilia 2012; 18 (03) e195-e200

Google Scholar
5 Shaikh AN, Khurshid M. Factor XIII deficiency in Pakistan. J Pak Med Assoc 1993; 43 (04) 67-69

Google Scholar
6 Dorgalaleh A, Tabibian S, Shams M. et al. A unique factor XIII mutation in southeastern Iran with an unexpectedly high prevalence: Khash factor XIII. Semin Thromb Hemost 2019; 45 (01) 43-49

Google Scholar
7 Naderi M, Dorgalaleh A, Alizadeh S. et al. Clinical manifestations and management of life-threatening bleeding in the largest group of patients with severe factor XIII deficiency. Int J Hematol 2014; 100 (05) 443-449

Google Scholar
8 Dorgalaleh A, Naderi M, Shamsizadeh M. Morbidity and mortality in a large number of Iranian patients with severe congenital factor XIII deficiency. Ann Hematol 2016; 95 (03) 451-455

Google Scholar
9 Muszbek L, Katona É. Diagnosis and management of congenital and acquired FXIII deficiencies. Semin Thromb Hemost 2016; 42 (04) 429-439

Google Scholar
10 Ivaskevicius V, Biswas A, Loreth R. et al. Mutations affecting disulphide bonds contribute to a fairly common prevalence of F13B gene defects: results of a genetic study in 14 families with factor XIII B deficiency. Haemophilia 2010; 16 (04) 675-682

Google Scholar
11 Ivaskevicius V, Biswas A, Bevans C. et al. Identification of eight novel coagulation factor XIII subunit A mutations: implied consequences for structure and function. Haematologica 2010; 95 (06) 956-962

Google Scholar
12 Seitz R, Duckert F, Lopaciuk S, Muszbek L, Rodeghiero F, Seligsohn U. Study Group. ETRO Working Party on Factor XIII questionnaire on congenital factor XIII deficiency in Europe: status and perspectives. Semin Thromb Hemost 1996; 22 (05) 415-418

Google Scholar
13 Mannucci PM. Bleeding symptoms in heterozygous factor XIII [corrected] deficiency. Haematologica 2010; 95 (09) e6

Google Scholar
14 Schroeder V, Kohler HP. Factor XIII deficiency: an update. Semin Thromb Hemost 2013; 39 (06) 632-641

Google Scholar
15 Biswas A, Ivaskevicius V, Thomas A, Oldenburg J. Coagulation factor XIII deficiency. Diagnosis, prevalence and management of inherited and acquired forms. Hamostaseologie 2014; 34 (02) 160-166

Google Scholar
16 Duckert F, Jung E, Shmerling DH. A hitherto undescribed congenital haemorrhagic diathesis probably due to fibrin stabilizing factor deficiency. Thromb Diath Haemorrh 1960; 5 (02) 179-186

Google Scholar
17 Egbring R, Seitz R, Gürten GV. et al. Bleeding complications in heterozygotes with congenital factor XIII deficiency. In: Mosesson MW, Amrani DL, Siebenlist KR, DiOrio JP, eds. Fibrinogen 3: Biochemistry, Biological Functions, Gene Regulation and Expression. Amsterdam: Elsevier 1988;341–346
18 Egbring R, Rohner I, Lerch L, Fuchs G, Kröniger A, Seitz R. Bleeding complications in patients with heterozygous FXIII subunit A deficiency?. Blood Coagul Fibrinolysis 1995; 6: 340

Google Scholar
19 Egbring R, Kröniger A, Seitz R. Factor XIII deficiency: pathogenic mechanisms and clinical significance. Semin Thromb Hemost 1996; 22 (05) 419-425

Google Scholar
20 Mahmoodi M, Peyvandi F, Afrasiabi A, Ghaffarpasand F, Karimi M. Bleeding symptoms in heterozygous carriers of inherited coagulation disorders in southern Iran. Blood Coagul Fibrinolysis 2011; 22 (05) 396-401

Google Scholar
21 Fisher S, Rikover M, Naor S. Factor 13 deficiency with severe hemorrhagic diathesis. Blood 1966; 28 (01) 34-39

Google Scholar
22 Ikkala E, Myllylae G, Nevanlinna HR. Transfusion therapy in factor XIII (FSF) deficiency. Scand J Haematol 1964; 1 (04) 308-312

Google Scholar
23 Ivaskevicius V, Seitz R, Kohler HP. et al; Study Group. International registry on factor XIII deficiency: a basis formed mostly on European data. Thromb Haemost 2007; 97 (06) 914-921

Google Scholar
24 Weiss A, Lee KC, Brumund KT, Chang DC, Bouvet M. Risk factors for hematoma after thyroidectomy: results from the nationwide inpatient sample. Surgery 2014; 156 (02) 399-404

Google Scholar
25 Ivaskevicius V, Windyga J, Baran B. et al. Phenotype-genotype correlation in eight Polish patients with inherited Factor XIII deficiency: identification of three novel mutations. Haemophilia 2007; 13 (05) 649-657

Google Scholar
26 Jia S, He Y, Lu M. et al. Identification of novel pathogenic F13A1 mutation and novel NBEAL2 gene missense mutation in a pedigree with hereditary congenital factor XIII deficiency. Gene 2019; 702 (02) 143-147

Google Scholar
27 Moret A, Zúñiga Á, Ayala JM. et al. Factor XIII deficiency in two Spanish families with a novel variant in gene F13A1 detected by next-generation sequencing; symptoms and clinical management. J Thromb Thrombolysis 2020; 50 (03) 686-688

Google Scholar
28 Deng J, Li D, Mei H, Tang L, Wang HF, Hu Y. Novel deep intronic mutation in the coagulation factor XIII a chain gene leading to unexpected RNA splicing in a patient with factor XIII deficiency. BMC Med Genet 2020; 21 (01) 9

Google Scholar
29 Shen MC, Chen M, Chang SP, Lin PT, Hsieh HN, Lin KH. Segmental uniparental disomy as a rare cause of congenital severe factor XIII deficiency in a girl with only one heterozygous carrier parent. Pediatr Hematol Oncol 2018; 35 7-8 442-446

Google Scholar
30 Sun L, Yan Q, Wang Y. et al. Pathogenicity analysis of variations and prenatal diagnosis in a hereditary coagulation factor XIII deficiency family. Hematology 2018; 23 (08) 501-509

Google Scholar
31 Handrkova H, Borhany M, Schroeder V. et al. Identification of two novel missense mutations causing severe factor XIII deficiency. Haemophilia 2015; 21 (03) e253 –e256

Google Scholar
32 Borhany M, Handrková H, Cairo A. et al. Congenital factor XIII deficiency in Pakistan: characterization of seven families and identification of four novel mutations. Haemophilia 2014; 20 (04) 568-574

Google Scholar
33 Farah RA, Al Danaf JZ, Chahinian RA. et al. Spontaneous epidural hematoma in a child with inherited factor XIII deficiency. J Pediatr Hematol Oncol 2014; 36 (01) 62-65

Google Scholar
34 Souri M, Biswas A, Misawa M, Omura H, Ichinose A. Severe congenital factor XIII deficiency caused by novel W187X and G273V mutations in the F13A gene; diagnosis and classification according to the ISTH/SSC guidelines. Haemophilia 2014; 20 (02) 255-262

Google Scholar
35 Castaman G, Giacomelli SH, Schroeder V. et al. Further evidence of heterogeneity of gene defects in Italian families with factor XIII deficiency. Haemophilia 2012; 18 (01) e6 –e8

Google Scholar
36 Castaman G, Giacomelli SH, Ivaskevicius V. et al. Molecular characterization of five Italian families with inherited severe factor XIII deficiency. Haemophilia 2008; 14 (01) 96-102

Google Scholar
37 Halverstadt A, Walsh S, Roth SM, Ferrell RE, Hagberg JM. Identification of a novel mutation combination in factor XIII deficiency: genetic update to the first reported case in the United States. Int J Hematol 2006; 83 (02) 144-146

Google Scholar
38 Bamberg C, Mickley L, Henkelmann A. et al. The impact of antenatal factor XIII levels on postpartum haemorrhage: a prospective observational study. Arch Gynecol Obstet 2019; 299 (02) 421-430

Google Scholar
39 Naderi M, Mirzaei I, Yaghoubi S, Milani I, Cohan N. Postpartum hemorrhage in heterozygote factor XIII deficient women compared with healthy women. A cross-sectional experience from Iran. Clin Appl Thromb Hemost 2021; 27: 107 60296211051714

Google Scholar
40 Karlsson O, Jeppsson A, Hellgren M. A longitudinal study of factor XIII activity, fibrinogen concentration, platelet count and clot strength during normal pregnancy. Thromb Res 2014; 134 (03) 750-752

Google Scholar
41 Haslinger C, Korte W, Hothorn T, Brun R, Greenberg C, Zimmermann R. The impact of prepartum factor XIII activity on postpartum blood loss. J Thromb Haemost 2020; 18 (06) 1310-1319

Google Scholar
42 Karlsson O, Jeppsson A, Hellgren M. Factor XIII activity at onset of labour and association with postpartum haemorrhage: an exploratory post-hoc study. Int J Obstet Anesth 2021; 47: 103174

Google Scholar
43 Xiang H, Wang C, Pan H. et al. Exome-sequencing identifies novel genes associated with recurrent pregnancy loss in a Chinese cohort. Front Genet 2021; 12 (12) 746082

Google Scholar
44 de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. Semin Thromb Hemost 2013; 39 (06) 585-595

Google Scholar
45 Inbal A, Muszbek L. Coagulation factor deficiencies and pregnancy loss. Semin Thromb Hemost 2003; 29 (02) 171-174

Google Scholar
46 Sharief LA, Kadir RA. Congenital factor XIII deficiency in women: a systematic review of literature. Haemophilia 2013; 19 (06) e349-e357

Google Scholar
47 Cerenzia G, Serrao L, Carillo C, Manna MR, Niccoli VS. Congenital factor XIII deficiency in pregnancy. A case report [Italian]. Minerva Ginecol 1999; 51 (10) 409-412

Google Scholar
48 Padmanabhan LD, Mhaskar R, Mhaskar A, Ross CR. Factor XIII deficiency: a rare cause of repeated abortions. Singapore Med J 2004; 45 (04) 186-187

Google Scholar
49 Bick RL. Recurrent miscarriage syndrome and infertility caused by blood coagulation protein or platelet defects. Hematol Oncol Clin North Am 2000; 14 (05) 1117-1131

Google Scholar
50 Fu M, Liu J, Xing J. et al. Reference intervals for coagulation parameters in non-pregnant and pregnant women. Sci Rep 2022; 12 (01) 1519

Google Scholar
51 Coopland A, Alkjaersig N, Fletcher AP. Reduction in plasma factor 13 (fibrin stabilizing factor) concentration during pregnancy. J Lab Clin Med 1969; 73 (01) 144-153

Google Scholar
52 Sharief LT, Lawrie AS, Mackie IJ, Smith C, Peyvandi F, Kadir RA. Changes in factor XIII level during pregnancy. Haemophilia 2014; 20 (02) e144-e148

Google Scholar
53 van Wersch JW, Vooijs ME, Ubachs JM. Coagulation factor XIII in pregnant smokers and non-smokers. Int J Clin Lab Res 1997; 27 (01) 68-71

Google Scholar
54 Sharief LA. Reproduction and Coagulation Factor XIII in Women. Doctoral Dissertation. University College London, London; 2013
55 Kobayashi T, Terao T, Kojima T, Takamatsu J, Kamiya T, Saito H. Congenital factor XIII deficiency with treatment of factor XIII concentrate and normal vaginal delivery. Gynecol Obstet Invest 1990; 29 (03) 235-238

Google Scholar
56 Burrows RF, Ray JG, Burrows EA. Bleeding risk and reproductive capacity among patients with factor XIII deficiency: a case presentation and review of the literature. Obstet Gynecol Surv 2000; 55 (02) 103-108

Google Scholar
57 Zhang X, Du W, Fang Q. Risk factors for postoperative haemorrhage after total thyroidectomy: clinical results based on 2,678 patients. Sci Rep 2017; 7 (01) 7075

Google Scholar
58 Lak M, Peyvandi F, Ali Sharifian A, Karimi K, Mannucci PM. Pattern of symptoms in 93 Iranian patients with severe factor XIII deficiency. J Thromb Haemost 2003; 1 (08) 1852-1853

Google Scholar
59 Korte W, Hinnen C, Degiacomi P. et al. XIII deficiency in the surgical intensive care unit is more frequent than a relevant fibrinogen deficiency. Haemostaseologie 2007; 27: A61

Google Scholar
60 Korte W. F. XIII in perioperative coagulation management. Baillieres Best Pract Res Clin Anaesthesiol 2010; 24 (01) 85-93

Google Scholar
61 Johansson PI, Sørensen AM, Perner A. et al. Disseminated intravascular coagulation or acute coagulopathy of trauma shock early after trauma? An observational study. Crit Care 2011; 15 (06) R272

Google Scholar
62 Sorensen B, Fries D. Emerging treatment strategies for trauma-induced coagulopathy. Br J Surg 2012; 99 (1, Suppl 1): 40-50

Google Scholar
63 Fries D, Streif W, Margreiter J. et al. The effects of perioperatively administered crystalloids and colloids on concentrations of molecular markers of activated coagulation and fibrinolysis. Blood Coagul Fibrinolysis 2004; 15 (03) 213-219

Google Scholar
64 Gerlach R, Raabe A, Zimmermann M, Siegemund A, Seifert V. Factor XIII deficiency and postoperative hemorrhage after neurosurgical procedures. Surg Neurol 2000; 54 (03) 260-264 , discussion 264–265

Google Scholar
65 Gerlach R, Tölle F, Raabe A, Zimmermann M, Siegemund A, Seifert V. Increased risk for postoperative hemorrhage after intracranial surgery in patients with decreased factor XIII activity: implications of a prospective study. Stroke 2002; 33 (06) 1618-1623

Google Scholar
66 Korte WC, Szadkowski C, Gähler A. et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology 2009; 110 (02) 239-245

Google Scholar
67 Gödje O, Gallmeier U, Schelian M, Grünewald M, Mair H. Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thorac Cardiovasc Surg 2006; 54 (01) 26-33

Google Scholar
68 Kanda A, Kaneko K, Obayashi O, Mogami A. The massive bleeding after the operation of hip joint surgery with the acquired haemorrhagic coagulation factor XIII(13) deficiency: two case reports. Case Rep Orthop 2013; 2013: 473014-473017

Google Scholar
69 Watanabe N, Yokoyama Y, Ebata T. et al. Clinical influence of preoperative factor XIII activity in patients undergoing pancreatoduodenectomy. HPB (Oxford) 2017; 19 (11) 972-977

Google Scholar
70 Gemmati D, Zeri G, Orioli E. et al. Factor XIII-A dynamics in acute myocardial infarction: a novel prognostic biomarker?. Thromb Haemost 2015; 114 (01) 123-132

Google Scholar
71 von Meijenfeldt FA, Havervall S, Adelmeijer J. et al. COVID-19 is associated with an acquired factor XIII deficiency. Thromb Haemost 2021; 121 (12) 1668-1669

Google Scholar
72 Dragu A, Bach AD, Leffler M, Unglaub F, Horch RE. Acute and diffuse postoperative bleeding after free latissimus dorsi flap--Factor XIII deficiency: a case report and review of the literature. Med Sci Monit 2009; 15 (01) CS1 –CS4

Google Scholar
73 Bagoly Z, Koncz Z, Hársfalvi J, Muszbek L. Factor XIII, clot structure, thrombosis. Thromb Res 2012; 129 (03) 382-387

Google Scholar
74 Duval C, Ali M, Chaudhry WW, Ridger VC, Ariëns RA, Philippou H. Factor XIII A-subunit V34L variant affects thrombus cross-linking in a murine model of thrombosis. Arterioscler Thromb Vasc Biol 2016; 36 (02) 308-316

Google Scholar
75 Muszbek L, Bagoly Z, Cairo A, Peyvandi F. Novel aspects of factor XIII deficiency. Curr Opin Hematol 2011; 18 (05) 366-372

Google Scholar
76 Supsrisunjai C, Hsu CK, Michael M. et al. Coagulation factor XIII-A subunit missense mutation in the pathobiology of autosomal dominant multiple dermatofibromas. J Invest Dermatol 2020; 140 (03) 624-635.e7

Google Scholar
77 Medeiros AD, Silva AV, Lima FP, Vasconcelos CV, Macedo LM, Melo NM. Effect of factor XIII on the healing of rat skin in use of corticosteroid. Revis Colé Bras Cirurg 2002; 29: 324-329

Google Scholar
78 Dorgalaleh A, Bahraini M, Shams M. et al. Molecular basis of rare congenital bleeding disorders. Blood Rev 2022; 9: 101029

Google Scholar
79 Ma S, Chen C, Liang Q. et al. Phenotype and genotype of FXIII deficiency in two unrelated probands: identification of a novel F13A1 large deletion mediated by complex rearrangement. Orphanet J Rare Dis 2019; 14 (01) 182

Google Scholar
80 Anwar R, Miloszewski KJ, Markham AF. Identification of a large deletion, spanning exons 4 to 11 of the human factor XIIIA gene, in a factor XIII-deficient family. Blood 1998; 91 (01) 149-153

Google Scholar
81 Thomas A, Ivaškevičius V, Zawadzki C, Goudemand J, Biswas A, Oldenburg J. Characterization of a novel large deletion caused by double-stranded breaks in 6-bp microhomologous sequences of intron 11 and 12 of the F13A1 gene. Hum Genome Var 2016; 3 (01) 15059

Google Scholar
82 Ivaškevičius V, Biswas A, Garly ML, Oldenburg J. Comparison of F13A1 gene mutations in 73 patients treated with recombinant FXIII-A₂ . Haemophilia 2017; 23 (03) e194-e203

Google Scholar
83 Souri M, Yee VC, Fujii N, Ichinose A. Molecular modeling predicts structural changes in the A subunit of factor XIII caused by two novel mutations identified in a neonate with severe congenital factor XIII deficiency. Thromb Res 2012; 130 (03) 506-510

Google Scholar
84 Biswas A, Ivaskevicius V, Thomas A. et al. Eight novel F13A1 gene missense mutations in patients with mild FXIII deficiency: in silico analysis suggests changes in FXIII-A subunit structure/function. Ann Hematol 2014; 93 (10) 1665-1676

Google Scholar
85 Thomas A, Biswas A, Dodt J. et al. Coagulation factor XIIIA subunit missense mutations affect structure and function at the various steps of factor XIII action. Hum Mutat 2016; 37 (10) 1030-1041

Google Scholar
86 Li B, Billur R, Maurer MC. et al. Proline 36 of the factor XIII activation peptide plays a crucial role in substrate recognition and zymogen activation. Thromb Haemost 2018; 118 (12) 2037-2045

Google Scholar

RSS-Feed abonnieren

Teilen / Bookmarken

Novel Insights into Heterozygous Factor XIII Deficiency

Abstract

Keywords

Publikationsverlauf

References